WallStreetZenWallStreetZen

NASDAQ: CYCC
Cyclacel Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Cyclacel Pharmaceuticals revenue was $43.00k for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $0.0, down 100% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CYCC annual revenue was $43.0k, with -89.8% growth year-over-year.

CYCC past revenue growth

How has CYCC's revenue growth performed historically?

Company
-89.76%
Industry
497.69%
Market
20.68%
CYCC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CYCC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

CYCC revenue history

Current Revenue
$43.0k
Current Earnings
-$11.2M
Current Profit Margin
-26,074.4%

Be the first to know when CYCC announces revenue.

CYCC Revenue History By Year

CYCC Yearly RevenueCYCC RevenueCYCC ChangeCYCC Revenue Growth
2024-12-31$43.00k-$377.00k-89.76%
2023-12-31$420.00kN/AN/A
2022-12-31$0.00N/AN/A
2021-12-31$0.00N/AN/A
2020-12-31$0.00N/AN/A
2019-12-31$0.00-$150.00k-100.00%
2018-12-31$150.00kN/AN/A
2017-12-31$0.00-$843.00k-100.00%
2016-12-31$843.00k-$1.10M-56.64%
2015-12-31$1.94M$210.00k+12.11%
2014-12-31$1.73M$650.00k+59.96%
2013-12-31$1.08M$1.02M+1,471.01%
2012-12-31$69.00kN/AN/A
2011-12-31$0.00-$112.00k-100.00%
2010-12-31$112.00k-$799.00k-87.71%
2009-12-31$911.00k$34.00k+3.88%
2008-12-31$877.00k$748.00k+579.84%
2007-12-31$129.00k-$258.00k-66.67%
2006-12-31$387.00k$31.00k+8.71%
2005-12-31$356.00k-$569.00k-61.51%
2004-12-31$925.00k$755.00k+444.12%
2003-12-31$170.00kN/AN/A
2002-12-31$0.00-$30.00k-100.00%
2001-12-31$30.00kN/AN/A

1 of 2

Cyclacel Pharmaceuticals Revenue FAQ

What was CYCC's revenue last quarter?

On Invalid Date, Cyclacel Pharmaceuticals (NASDAQ: CYCC) reported Q4 2024 revenue of $0.00 up 100% year over year. In the same quarter last year, Cyclacel Pharmaceuticals's revenue was $31.00 thousand.

What was Cyclacel Pharmaceuticals's revenue in 2024?

Cyclacel Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $43.00 thousand, a 89.76% decrease year over year.

How much does Cyclacel Pharmaceuticals make in a day?

Based on Cyclacel Pharmaceuticals annual revenue for the past five years, CYCC makes an average of $253.70 per day.

What was Cyclacel Pharmaceuticals's annual revenue growth in the past year?

As of Q2 2025, Cyclacel Pharmaceuticals's revenue has grown -89.76% year over year. This is 587.46 percentage points lower than the US Biotechnology industry revenue growth rate of 497.69%. Cyclacel Pharmaceuticals's revenue in the past year totaled $43.00 thousand.

How much does Cyclacel Pharmaceuticals make in a year?

Cyclacel Pharmaceuticals's revenue by year for the past five years is:
  • Cyclacel Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $43.00 thousand, a 89.76% decrease year over year.
  • Cyclacel Pharmaceuticals's annual revenue for Dec 31, 2023 was $420.00 thousand, a Infinity% increase from 2022.
  • Cyclacel Pharmaceuticals's annual revenue for 2022 was $0.00, a N/A decrease from 2021.
  • Cyclacel Pharmaceuticals's annual revenue for 2021 was $0.00, a N/A decrease from 2020.
  • Cyclacel Pharmaceuticals's annual revenue for 2020 was $0.00, a N/A decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.